Literature DB >> 20726986

Emodin suppresses lipopolysaccharide-induced pro-inflammatory responses and NF-κB activation by disrupting lipid rafts in CD14-negative endothelial cells.

Guoquan Meng1, Yiyao Liu, Changchun Lou, Hong Yang.   

Abstract

BACKGROUND AND
PURPOSE: Emodin [1,3,8-trihydroxy-6-methylanthraquinone] has been reported to exhibit vascular anti-inflammatory properties. However, the corresponding mechanisms are not well understood. The present study was designed to explore the molecular target(s) of emodin in modifying lipopolysaccharide (LPS)-associated signal transduction pathways in endothelial cells. EXPERIMENTAL APPROACH: Cultured primary human umbilical vein endothelial cells (HUVECs; passages 3-5) were pre-incubated with emodin (1-50 µg·mL(-1) ). LPS-induced expression of pro-inflammatory cytokines [interleukin (IL)-1β, IL-6] and chemokines (IL-8; CCL2/MCP-1) were determined by reverse transcription-PCR and elisa. Nuclear factor-κB (NF-κB) activation, inhibitor of κB (IκB)α degradation and Toll-like receptor-4 (TLR-4) were detected by immunocytochemistry and Western blotting. Cholesterol depletion [by methyl β-cyclodextrin (MBCD), a specific cholesterol binding agent] and cholesterol replenishment were further used to investigate the roles of lipid rafts in activation of HUVECs. KEY
RESULTS: Emodin inhibited, concentration-dependently, the expression of LPS-induced pro-inflammatory cytokines (IL-1β, IL-6) and chemokines (IL-8, CCL2) and, in parallel, inhibited NF-κB activation and IκBα degradation in HUVECs. However, emodin did not inhibit the NF-κB activation and IκBα degradation induced by IL-1β. The cholesterol binding agent, MBCD, inhibited LPS-induced NF-κB activation in passaged HUVECs [which also lack the LPS receptor, membrane CD14 (mCD14)], showing that lipid rafts played a key role in LPS signalling in mCD14-negative HUVECs. Moreover, emodin disrupted the formation of lipid rafts in cell membranes by depleting cholesterol. CONCLUSIONS AND IMPLICATIONS: Lipid rafts were crucial in facilitating inflammatory responses of mCD14-negative HUVECs to LPS. Emodin disrupted lipid rafts through depleting cholesterol and, consequently, inhibited inflammatory responses in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726986      PMCID: PMC3010572          DOI: 10.1111/j.1476-5381.2010.00993.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  A CD14-independent LPS receptor cluster.

Authors:  K Triantafilou; M Triantafilou; R L Dedrick
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 2.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

3.  Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes.

Authors:  F X Zhang; C J Kirschning; R Mancinelli; X P Xu; Y Jin; E Faure; A Mantovani; M Rothe; M Muzio; M Arditi
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

4.  Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells.

Authors:  E Faure; O Equils; P A Sieling; L Thomas; F X Zhang; C J Kirschning; N Polentarutti; M Muzio; M Arditi
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

Review 5.  The role of the endothelium in modulating vascular control in sepsis and related conditions.

Authors:  S J Wort; T W Evans
Journal:  Br Med Bull       Date:  1999       Impact factor: 4.291

Review 6.  Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis.

Authors:  Douglas D Bannerman; Simeon E Goldblum
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-06       Impact factor: 5.464

7.  Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2.

Authors:  Kimberly A Walton; Amy L Cole; Michael Yeh; Ganesamoorthy Subbanagounder; Stephan R Krutzik; Robert L Modlin; Robert M Lucas; Junko Nakai; Eric J Smart; Deven K Vora; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-29       Impact factor: 8.311

Review 8.  Lipid rafts: bringing order to chaos.

Authors:  Linda J Pike
Journal:  J Lipid Res       Date:  2003-02-01       Impact factor: 5.922

9.  Fluorescence recovery after photobleaching reveals that LPS rapidly transfers from CD14 to hsp70 and hsp90 on the cell membrane.

Authors:  K Triantafilou; M Triantafilou; S Ladha; A Mackie; R L Dedrick; N Fernandez; R Cherry
Journal:  J Cell Sci       Date:  2001-07       Impact factor: 5.285

10.  Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation.

Authors:  Martha Triantafilou; Kensuke Miyake; Douglas T Golenbock; Kathy Triantafilou
Journal:  J Cell Sci       Date:  2002-06-15       Impact factor: 5.285

View more
  38 in total

1.  Cyanidin-3-O-β-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model.

Authors:  Yunhe Fu; Zhengkai Wei; Ershun Zhou; Naisheng Zhang; Zhengtao Yang
Journal:  J Lipid Res       Date:  2014-04-21       Impact factor: 5.922

2.  Emodin induces apoptosis of concanavalin A-stimulated murine splenocytes.

Authors:  Subin An; So Jin Bing; Jinhee Cho; Kalahe Hewage Iresha Nadeeka Madushani Herath; Areum Kim; Hyeun Wook Chang; Youngheun Jee
Journal:  Food Sci Biotechnol       Date:  2016-12-31       Impact factor: 2.391

3.  Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States.

Authors:  Sarah A Woller; Soo-Ho Choi; Eun Jung An; Hann Low; Dina A Schneider; Roshni Ramachandran; Jungsu Kim; Yun Soo Bae; Dmitri Sviridov; Maripat Corr; Tony L Yaksh; Yury I Miller
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

4.  Emodin inhibits tonic tension through suppressing PKCδ-mediated inhibition of myosin phosphatase in rat isolated thoracic aorta.

Authors:  Kyung-Min Lim; Jae-Hyuk Kwon; Keunyoung Kim; Ji-Yoon Noh; Seojin Kang; Jung-Min Park; Moo-Yeol Lee; Ok-Nam Bae; Jin-Ho Chung
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

5.  AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation.

Authors:  Soo-Ho Choi; Aaron M Wallace; Dina A Schneider; Elianne Burg; Jungsu Kim; Elena Alekseeva; Niki Dj Ubags; Carlyne D Cool; Longhou Fang; Benjamin T Suratt; Yury I Miller
Journal:  JCI Insight       Date:  2018-08-23

6.  Lipid Rafts Promote trans Fatty Acid-Induced Inflammation in Human Umbilical Vein Endothelial Cells.

Authors:  Yao Pan; Benxin Liu; Zeyuan Deng; Yawei Fan; Jing Li; Hongyan Li
Journal:  Lipids       Date:  2016-11-16       Impact factor: 1.880

7.  Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.

Authors:  Zhen-Hua Sun; Ping Bu
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

8.  Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1.

Authors:  Wei Qu; Yufei Wang; Qining Wu; Jijun Liu; Dingjun Hao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

9.  Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.

Authors:  Gang Chen; Hong Qiu; Shan-Dong Ke; Shao-Ming Hu; Shi-Ying Yu; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

10.  Emodin attenuates systemic and liver inflammation in hyperlipidemic mice administrated with lipopolysaccharides.

Authors:  Xuemei Jia; Stephen Iwanowycz; Junfeng Wang; Fatma Saaoud; Fang Yu; Yuzhen Wang; Jun Hu; Saurabh Chatterjee; Qian Wang; Daping Fan
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.